Tryptamine Therapeutics (ASX: TYP) has secured a new R&D loan facility with Rockford Equity — giving it extra firepower to accelerate its clinical programs - with its binge eating disorder drug, TRP-8803, at the forefront.
The agreement provides a line of credit of up to $2.6 million, secured against eligible R&D expenditure for FY26, and repayable through future R&D Tax Incentives. Funds can be drawn in $500,000 tranches, with interest at 16% per annum.
This bolsters Tryptamine’s strong cash position — and is set to be further boosted by an $800,000 R&D tax rebate this quarter.
Tryptamine's CEO, Jason Carroll, said: "The capital, if required will be used towards fast tracking a number of key development milestones, including our TRP-8803 trial into BED with Swinburne University, as well as other opportunities which are very well advanced".
#ASXNews #Biotech #ClinicalTrials #BingeEatingDisorder #RDTaxIncentive #TryptamineTherapeutics #PharmaInnovation #DrugDevelopment #MedicalResearch #ASX